PrefacePrefaceCiulla, Thomas MD, MBA; Pennesi, Mark E. MD, PhD; Kiss, Szilárd MD; Cunningham, Emmett T. Jr MD, PhD, MPHAuthor Information Equity and salary from Clearside to T.C., MD, MBA. Consultant for Optos, Adverum, Regenxbio, Gyroscope, Regeneron, Genentech/Roche; research support from Optos; equity from Fortress Bio; and intellectual property related to gene and cellular therapy to S.K., MD. Data Safety Monitoring Board for Akous and Gensight; clinical trial support for FFB; consultant for 4D Molecular Therapetuics, Adverum, Astellas Pharmaceuticals, Blue Rock, IVERIC, Novartis, Ora, PYC Therapeutics, RegenexBio, Roche, Viewpoint Therapeutics; consultant and scientific advisory board for Eyevensys, Horama, Nayan, Sparing Vision, Vedere; consultant and clinical trial support for Biogen, AGTC, Editas, ProQR, Sanofi; consultant and equity with Endogena; consultant, equity, and clinical advisory board for Atsena; consultant, equity, and scientific advisory board for DTx, Nacuity Pharmaceuticals, Ocugen to M.E.P, MD, PhD. E.T.C. declares that there is no conflicts of interest to disclose. International Ophthalmology Clinics: Summer 2021 - Volume 61 - Issue 3 - p 1-2 doi: 10.1097/IIO.0000000000000371 Buy Metrics Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.